Neoadjuvant chemotherapy for resectable colorectal cancer liver metastases: Impact on magnitude of liver resection and survival

Gruenberger, T.; Schuell, B.; Kornek, Gabriela; Scheithauer, Werner

doi:10.1200/jco.2004.22.90140.3598

Cited by 10 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These attempts have however been unsuccessful [3][4][5] with the exception of a single centre trial from N. Kemeny's group [6]. Due to these unpleasant findings and the stunning re- T. Gruenberger sults of combination chemotherapy in the metastatic setting neoadjuvant treatment strategies in both resectable and primarily non optimal resectable colorectal cancer liver metastases have been undertaken [7][8][9]. First results of an EORTC trial comparing perioperative chemotherapy with surgery alone will become available in 2006.…”

Section: Commentmentioning

confidence: 94%

Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases

Gruenberger

2005

Eur Surg

Self Cite

View full text Add to dashboard Cite

The article by Koch et al. [1] is another piece of work for our understanding of the potential of colorectal cancer to metastasize through detection of peripheral tumour cells both in the blood stream as well as in the bone marrow.Primary aim of the study was a correlation of the long-term recurrence-free survival of curatively resected patients with colorectal cancer liver metastases (CRCLM) with their status of detected peripheral cancer cells during surgery. Thirty-seven patients were prospectively studied over a period of three years for the detection of disseminated cancer cells by reverse transcriptionpolymerase chain reaction (RT-PCR) both in blood and bone marrow perioperatively. All patients underwent a curative liver resection for their CRCLM and had blood samples taken after induction of anaesthesia, immediately following liver resection and 24 hours post resection. Bone marrow samples were obtained at the beginning of the operative procedure. Positivity of cancer cells detected was correlated with recurrence-free survival (RFS). Clinical and pathological characteristics of the 37 patients were heterogeneous but were analyzed both in univariate and multivariate analyses for their importance in regards to RFS.Tumour cells were detected in blood samples in 30% of the patients preoperatively, in 46% intra-operatively and in 22% postoperatively. Bone marrow was found positive for tumour cells in 16% of the investigated patients (25). 25 patients (68%) developed tumour recurrence after a median follow-up of 38 months with nearly half of them solitary in the liver. Interestingly a low incidence of well established negative prognostic factors would not assume such a high rate of recurrences (51% positive lymph node primary, 22% more than 2 CRCLM, 19% tumour size larger 5 cm). Univariate RFS analysis revealed significant differences for positive bone marrow samples, intraoperative blood samples and the number of positive blood samples. Although not statistically significant in univariate RFS analysis, all patients with positive postoperative blood samples developed tumour recurrence as did patients with positive bone marrow samples. Worth mentioning is the fact that up to 65% of the patients with blood sample negative for the detection of tumour cells developed recurrence. In a multivariate recurrence-free survival analysis, both intraoperative positive blood samples and positive bone marrow were identified as being significantly correlated with a worse outcome, although analyzed in two different models. A wellknown prognostic index established by Yuman Fong's group [2] in over 1000 resected patients with CRCLM did not reach significance in this model.The authors discuss the value of their findings in regards to adjuvant treatment concepts and surgical approaches to minimize intraoperative tumour cell dissemination. They conclude that the detection of tumour cells both in peripheral blood samples and in bone marrow samples has been identified as new prognostic marker which may change surgical technique and ma...

show abstract

Section: Commentmentioning

confidence: 94%

Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases

Gruenberger

2005

Eur Surg

Self Cite

View full text Add to dashboard Cite

show abstract

“…Even greater controversy exists over whether patients with resectable liver metastases should also receive neaodjuvant therapy where some have shown a low incidence of histologically involved resection margins when such an approach is used [111] whereas others have shown rates of histological involvement ranging from 9 to 19% overall [13,112]. This issue is further complicated by variable reports of substantially increased perioperative morbidity following hepatectomy in patients treated with neaodjuvant chemotherapy [36,111,113] or preoperative bevacizumab therapy [37].…”

Section: Neoadjuvant Chemotherapy: Current Controversiesmentioning

confidence: 97%

The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy

Chiappa

Makuuchi

Lygidakis

et al. 2009

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

“…The 3-year disease-free survival of 7% makes this approach at least questionable, especially if data from the same group are available that do not support this idea [4]. We have learned throughout recent years that patients with progression of disease under modern chemotherapeutic regimes should be spared liver resection due to early recurrence and death [5][6][7]. Therefore, patients with extrahepatic disease should receive chemotherapy to study their tumor biology before being offered a potentially curative treatment approach.…”

Section: Commentmentioning

confidence: 97%

First and repeat resection of colorectal liver metastases in elderly patients

Gruenberger

2005

Eur Surg

Self Cite

View full text Add to dashboard Cite

Neoadjuvant chemotherapy for resectable colorectal cancer liver metastases: Impact on magnitude of liver resection and survival

Cited by 10 publications

References 0 publications

Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases

Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases

The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy

First and repeat resection of colorectal liver metastases in elderly patients

Contact Info

Product

Resources

About